246 related articles for article (PubMed ID: 7624378)
1. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates.
Brouillet E; Hantraye P; Ferrante RJ; Dolan R; Leroy-Willig A; Kowall NW; Beal MF
Proc Natl Acad Sci U S A; 1995 Jul; 92(15):7105-9. PubMed ID: 7624378
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.
Beal MF; Brouillet E; Jenkins BG; Ferrante RJ; Kowall NW; Miller JM; Storey E; Srivastava R; Rosen BR; Hyman BT
J Neurosci; 1993 Oct; 13(10):4181-92. PubMed ID: 7692009
[TBL] [Abstract][Full Text] [Related]
3. Neurochemistry and toxin models in Huntington's disease.
Beal MF
Curr Opin Neurol; 1994 Dec; 7(6):542-7. PubMed ID: 7866587
[TBL] [Abstract][Full Text] [Related]
4. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease.
Palfi S; Ferrante RJ; Brouillet E; Beal MF; Dolan R; Guyot MC; Peschanski M; Hantraye P
J Neurosci; 1996 May; 16(9):3019-25. PubMed ID: 8622131
[TBL] [Abstract][Full Text] [Related]
5. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid.
Brouillet E; Jenkins BG; Hyman BT; Ferrante RJ; Kowall NW; Srivastava R; Roy DS; Rosen BR; Beal MF
J Neurochem; 1993 Jan; 60(1):356-9. PubMed ID: 8417157
[TBL] [Abstract][Full Text] [Related]
6. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid.
Andreassen OA; Ferrante RJ; Beal MF; Jørgensen HA
Neuroscience; 1998 Dec; 87(3):639-48. PubMed ID: 9758230
[TBL] [Abstract][Full Text] [Related]
7. Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.
Klivenyi P; Starkov AA; Calingasan NY; Gardian G; Browne SE; Yang L; Bubber P; Gibson GE; Patel MS; Beal MF
J Neurochem; 2004 Mar; 88(6):1352-60. PubMed ID: 15009635
[TBL] [Abstract][Full Text] [Related]
8. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats.
Borlongan CV; Koutouzis TK; Randall TS; Freeman TB; Cahill DW; Sanberg PR
Brain Res Bull; 1995; 36(6):549-56. PubMed ID: 7538873
[TBL] [Abstract][Full Text] [Related]
9. The 3-NP Model of Striatal Neurodegeneration.
Brouillet E
Curr Protoc Neurosci; 2014 Apr; 67():9.48.1-9.48.14. PubMed ID: 24723322
[TBL] [Abstract][Full Text] [Related]
10. 3-Nitropropionic acid animal model and Huntington's disease.
Borlongan CV; Koutouzis TK; Sanberg PR
Neurosci Biobehav Rev; 1997 May; 21(3):289-93. PubMed ID: 9168265
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial impairment induced by 3-nitropropionic acid is enhanced by endogenous metalloprotease activity inhibition in cultured rat striatal neurons.
de Oca Balderas PM; Ospina GG; Del Ángel AS
Neurosci Lett; 2013 Jun; 546():16-20. PubMed ID: 23643981
[TBL] [Abstract][Full Text] [Related]
12. Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid.
Dautry C; Condé F; Brouillet E; Mittoux V; Beal MF; Bloch G; Hantraye P
Neurobiol Dis; 1999 Aug; 6(4):259-68. PubMed ID: 10448053
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease.
Roitberg BZ; Emborg ME; Sramek JG; Palfi S; Kordower JH
Neurosurgery; 2002 Jan; 50(1):137-45; discussion 145-6. PubMed ID: 11844244
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington's disease-like symptoms in rats.
Danduga RCSR; Dondapati SR; Kola PK; Grace L; Tadigiri RVB; Kanakaraju VK
Biomed Pharmacother; 2018 Sep; 105():1254-1268. PubMed ID: 30021362
[TBL] [Abstract][Full Text] [Related]
15. Replicating Huntington's disease phenotype in experimental animals.
Brouillet E; Condé F; Beal MF; Hantraye P
Prog Neurobiol; 1999 Dec; 59(5):427-68. PubMed ID: 10515664
[TBL] [Abstract][Full Text] [Related]
16. Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease.
Burns LH; Pakzaban P; Deacon TW; Brownell AL; Tatter SB; Jenkins BG; Isacson O
Neuroscience; 1995 Feb; 64(4):1007-17. PubMed ID: 7753372
[TBL] [Abstract][Full Text] [Related]
17. Role of Rho Kinase Inhibition in the Protective Effect of Fasudil and Simvastatin Against 3-Nitropropionic Acid-Induced Striatal Neurodegeneration and Mitochondrial Dysfunction in Rats.
Ahmed LA; Darwish HA; Abdelsalam RM; Amin HA
Mol Neurobiol; 2016 Aug; 53(6):3927-3938. PubMed ID: 26169112
[TBL] [Abstract][Full Text] [Related]
18. Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production.
Villarán RF; Tomás-Camardiel M; de Pablos RM; Santiago M; Herrera AJ; Navarro A; Machado A; Cano J
Neurotoxicology; 2008 Mar; 29(2):244-58. PubMed ID: 18093658
[TBL] [Abstract][Full Text] [Related]
19. Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Palfi S; Riche D; Brouillet E; Guyot MC; Mary V; Wahl F; Peschanski M; Stutzmann JM; Hantraye P
Exp Neurol; 1997 Jul; 146(1):135-41. PubMed ID: 9225746
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease.
Lee WT; Chang C
Prog Neurobiol; 2004 Feb; 72(2):87-110. PubMed ID: 15063527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
